Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 17/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7549509 | 1.00 | CCKBR (0.48) | CCKBRMEN1KMT2AHSD17B10CCKAR | |
| SCHEMBL7547317 | 0.95 | CCKBR (0.50) | CCKBRMEN1KMT2AHSD17B10 | |
| SCHEMBL7547309 | 0.95 | CCKBR (0.50) | CCKBRMEN1KMT2AHSD17B10 | |
| SCHEMBL7548027 | 0.91 | ALDH1A1 (0.43) | CCKBRMEN1KMT2AHSD17B10 | |
| SCHEMBL7548017 | 0.91 | ALDH1A1 (0.43) | CCKBRMEN1KMT2AHSD17B10 | |
| SCHEMBL7547435 | 0.88 | ALDH1A1 (0.43) | CCKBRMEN1KMT2AHSD17B10 | |
| SCHEMBL7547427 | 0.88 | ALDH1A1 (0.43) | CCKBRMEN1KMT2AHSD17B10 | |
| SCHEMBL7548490 | 0.87 | CCKAR (0.40) | CCKBRHSD17B10CCKAR | |
| SCHEMBL7544386 | 0.87 | CCKAR (0.42) | CCKBRCCKAR | |
| SCHEMBL7544380 | 0.87 | CCKAR (0.42) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CCKBR 2/4885MEN1 2261/4885KMT2A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.